Rethinking schizophrenia

  title={Rethinking schizophrenia},
  author={Thomas R. Insel},
  • T. Insel
  • Published 2010
  • Psychology, Medicine
  • Nature
How will we view schizophrenia in 2030? Schizophrenia today is a chronic, frequently disabling mental disorder that affects about one per cent of the world’s population. After a century of studying schizophrenia, the cause of the disorder remains unknown. Treatments, especially pharmacological treatments, have been in wide use for nearly half a century, yet there is little evidence that these treatments have substantially improved outcomes for most people with schizophrenia. These current… 
Bleuler and the neurobiology of schizophrenia.
  • S. Heckers
  • Psychology, Medicine
    Schizophrenia bulletin
  • 2011
The importance of Bleuler's monograph for the neuroscientific exploration of schizophrenia is reviewed, which assumed that schizophrenia has a neural basis but remained agnostic on possible mechanisms and skeptical about the value of pathological diagnosis.
The many roads to psychosis: recent advances in understanding risk and mechanisms
Recent advances that have led to changes in the understanding of risk factors and mechanisms involved in the development of schizophrenia are reviewed.
Thinking and schizophrenia: challenges and opportunities.
  • H. Tan
  • Psychology, Medicine
    Annals of the Academy of Medicine, Singapore
  • 2013
Several research perspectives I think might be particularly relevant to the Asia Pacifi c region that Singapore is part of are highlighted, including schizophrenia as a Complex but Solvable Genetic Disease and genome-wide association studies have yielded important new genetic mechanisms for a host of eye, metabolic and inflamatory bowel diseases.
Editorial: Antipsychotics of New Generation: Where Are We now?
Some progress was achieved to deeper understand molecular-cellular, biochemical and neurobiological mechanisms of schizophrenia during its neurodevelopment, and several potential drug targets for antipsychotics have emerged based on dysbindin1-related clinical and animal studies.
Altering the course of schizophrenia: progress and perspectives
A broad-based consideration of the challenges and opportunities inherent in efforts to alter the course of schizophrenia is provided, including 'hybrid' strategies that both relieve presenting symptoms and reduce the risk of transition to schizophrenia or another psychiatric disorder.
Schizophrenia: Its prevalence, consequences and effective pharmacist role
It is found that patients between the ages of 20 to 30 years want to get married and the ratio of suicidal attempt is 40% and in which about 13 to 15% patients became successful to attempt suicide.
The polygenic architecture of schizophrenia — rethinking pathogenesis and nosology
This Review summarizes the evidence for a polygenic architecture of schizophrenia that involves a large number of risk alleles across the whole range of population frequencies and suggests a substantial overlap between schizophrenia and psychiatric, behavioural and cognitive traits, which could influence future disease classifications and mechanistic research.
The Science of Psychiatry in Uncertain Times : What does the Future hold ?
The case is presented that the future of psychiatric research lies in the redefinition of psychiatric disease away from the classical kraepelinian dichotomy enshrined in psychiatric practice.
Research strategies and priorities to improve the lives of people with schizophrenia: executive summary of the Ernst Strüngmann Forum on schizophrenia.
An invited group of expert and experienced researchers with diverse scientific backgrounds from around the world explored novel ways of conceptualizing schizophrenia and integrating data across levels of analysis with the goal of accelerating advances in treatment development and prevention.


Common polygenic variation contributes to risk of schizophrenia and bipolar disorder
The extent to which common genetic variation underlies the risk of schizophrenia is shown, using two analytic approaches, and the major histocompatibility complex is implicate, which is shown to involve thousands of common alleles of very small effect.
A separate disease within the syndrome of schizophrenia.
It is proposed that deficit psychopathology (ie, enduring, idiopathic negative symptoms) defines a group of patients with a disease different from schizophrenia without deficit features, as the deficit and nondeficit groups differ in their signs and symptoms, course, biological correlates, treatment response, and etiologic factors.
What Are the Right Targets for Psychopharmacology?
This work focuses on dimensions of psychopathology or dysfunction more proximate to pathophysiology, which are not necessarily well represented in currently accepted clinical endpoints and consensus-derived diagnostic systems for mental disorders.
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
  • J. Coyle
  • Psychology, Medicine
    Cellular and Molecular Neurobiology
  • 2006
Hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia.
Understanding the Role of DISC1 in Psychiatric Disease and during Normal Development
A number of exciting areas of current DISC1 research are revealed that are revealing roles for DISC 1 during normal brain development and also in the disease state, which will provide a timely and exciting overview of the field and its potential in furthering the understanding of psychiatric diseases and in developing new therapies.
The NIMH-MATRICS consensus statement on negative symptoms.
A consensus development conference was held to review the data relating to the existence of separate domains within negative symptoms, as a prerequisite for choosing appropriate measures of these domains in clinical trials and to examine issues that may interfere with treatment development.
Schizophrenia: a disorder of neurodevelopment?
The current status of the dopamine hypothesis of schizophrenia.
  • A. Carlsson
  • Psychology, Medicine
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
  • 1988
[Dementia praecox or the group of schizophrenias].
It's coming again, the new collection that this site has; the favorite dementia praecox or the group of schizophrenias monograph series on schizophrenia no 1 book is offered today.